kate_black_23andme

23andMe appoints privacy officer

pharmafile | March 2, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  23andME, kate black 

US genetics testing firm 23andMe has appointed Kate Black as its privacy officer and corporate counsel.

As a member of the firm’s legal and regulatory team, Black will be responsible for reviewing and updating the company‘s privacy and consent policies for customers in the US and abroad. She joined 23andMe in January and reports to Kathy Hibbs, its chief legal and regulatory affairs officer.

Black joined the firm from the US Department of Health and Human Services in Washington, DC – where she served as a federal regulatory and interoperability policy analyst.

Advertisement

Black has also worked as health privacy counsel for the Center for Democracy and Technology in San Francisco, and earlier in her career on health tech policy initiatives at the White House – as well as serving as a pro bono researcher for The World Health Organization.

Hibbs says: “Last year, our company committed to hiring a privacy officer to help us ensure that our privacy and consent policies best complement our philosophy on the importance of customer choice and empowerment. While we have always had a team dedicated to this effort, we are thrilled to have Kate take a leadership role at 23andMe.”

Black adds: “The potential impact that 23andMe can have on both individual health and the entire healthcare industry is profound.” 

Related Content

23andMe to offer genetic reports on diabetes

Personal genomics company, 23andMe will offer customers information on the likelihood that they are genetically …

shutterstock_192094955_web

Widening the focus on innovations in cancer treatment

Cancer treatment is making leaps and bounds, but public focus tends to gravitate towards the …

gsk_boronia_australia

GSK forges $300m partnership with 23andMe to boost preclinical R&D

In a bid to supercharge its drug discovery efforts, GlaxoSmithKline has sealed a $300 million …

The Gateway to Local Adoption Series

Latest content